775-P: Effect of Optimized Settings during Six Months of Real-World MiniMed 780G Advanced Hybrid Closed-Loop (AHCL) Therapy Use in Chile

Background and Aims: The pivotal trial of the MiniMed™ 780G system showed that optimized settings of active insulin time (2 hours) and target glucose (100mg/dL) improved glycemic outcomes.1 This study analyzed real-world glycemic outcomes of individuals with T1D in Chile, 6 months after AHCL initiation with different settings. Methods: Data from 37 MiniMed™ 780G system users (aged 5-76 years, mean±SD of 29.3±19.3 years) at 12 centers throughout Chile were prospectively collected and analyzed. Effects of active insulin time (AIT) and glucose target on mean GMI, TIR (70-180mg/dL) , time at 180mg/dL (TAR) were determined using 14 days of sensor glucose data pre-AHCL and at 180 days post-AHCL initiation. Results: Overall TIR increased from 74.1% to 78.4% (p